ClinicalTrials.gg
CompletedNCT01999582Updated Jun 24, 2024Results posted

A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis

A Phase 2 interventional study of Sotatercept and Sotatercept in Anemia and Kidney Failure, Chronic, sponsored by Celgene. Completed at 23 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-24.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Anemia by Bristol-Myers Squibb — 1 open to participants now, 8 under way, 5 of them phase 3. Anemia · Bristol-Myers Squibb.

Enrollment
12th of 15
50 · median 189
Started
2013
the only one that year
Phase 2
6 of 16
none open now
Registered
4th of 16
by date

Among the 16 studies in Anemia by Bristol-Myers Squibb, this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2013, is one of 6 in phase 2, and was the 4th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 16 studies in Anemia by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Anemia by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

To determine the optimal route of administration, dose level, and safety of intravenous and subcutaneous dosing of sotatercept for maintaining hemoglobin levels in subjects who are on hemodialysis.

03

Conditions studied

  • Anemia
  • Kidney Failure, Chronic

Keywords

  • Anemia
  • End Stage Kidney Disease
  • Chronic Kidney Disease
  • Dialysis
  • Erythrpoietin Stimulating Agent (ESA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females ≥ 18 years of age.
  2. Subjects on at least 6 hours of hemodialysis per week, for at least 12 weeks before screening
  3. Subjects must be on a stable intravenous or subcutaneous dose of Erythropoietin Stimulating Agents (excluding methoxy polyethylene glycol-epoetin beta [Mircera]) to maintain .
  4. A mean predialysis hemoglobin concentration ≥ 10 g/dL (grams per deciliter) to ≤ 12 g/dL (≥ 100 g/L (grams per liter) to ≤ 120 g/L) obtained from three consecutive days.
  1. A value ≥ 18.5 kg/m2 (kilograms per m2) at screening. 5. Understand and voluntarily sign an document prior to any study related assessments/procedures are conducted.
  1. Able to adhere to the study visit schedule and comply with all protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Non renal causes of anemia
  2. Subjects on peritoneal dialysis.
  3. Systemic hematological disease
  4. Uncontrolled diabetes mellitus ( (hemoglobin A1c) > 9%) at screening.
  5. Uncontrolled hypertension defined as mean of home systolic blood pressure > 160 mm Hg (millimeter of mercury) or mean of home diastolic blood pressure > 90 mm Hg calculated once during the screening period prior to randomization
  6. Subjects with heart failure
  7. History of (except excised and cured non-melanoma skin cancer, or cervical carcinoma in situ that was surgically ablated more than 5 years ago).
  8. Anticipated or scheduled living donor renal transplant during the course of the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Intravenous Dose Group 1, 2, and 3

    Intravenous Dose Group 1 starting at 0.1 mg/kg and escalated in Dose Groups 2 (0.2 mg/kg) and Dose Group 3 (0.1, 0.2, 0.3, 0.4 mg/kg, titrated based on titration rules, administered every 14 days)

    Biological: Sotatercept

  • Experimental
    Subcutaneous Dose Group 1, 2, and 3

    Subcutaneous Dose Group 1 starting at 0.13 mg/kg and escalated in Dose Groups 2 (0.26 mg/kg) and Dose Group 3 (0.4 to 0.5 mg/kg, titrated based on titration rules, administered every14 days)

    Biological: Sotatercept

Interventions

  • BiologicalSotatercept

    Sotatercept is dosed intravenously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.

    Also known as: ACE-011

  • BiologicalSotatercept

    Sotatercept is dosed subcutaneously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.

    Also known as: ACE-011

06

What researchers measure

Primary outcomes

  1. Area Under the Serum Concentration-Time Curve Over Dosing Interval (AUC14d) (14 Days)

    Area Under the plasma concentration-time curve over 14-day dosing interval (AUC14) for Sotatercept., The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.

    Time frame: Doses 1-2: predose and postdose at 5 min (IV only) 4 hours, 3, and 7 days after each dose; Doses 3-7: predose, and postdose at 5 min after IV injection after each dose; Final dose: predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14 days after dose

  2. Area Under the Serum Concentration- Time Curve Over From Day 1 to Day 28 (AUC28d)

    Area under the plasma concentration-time curve over 28-day dosing interval (AUC28d). All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.

    Time frame: Doses 1-2: predose and postdose at 5 min (IV only) 4 hours, 3, and 7 days after each dose; Doses 3-7: predose, and postdose at 5 min after IV injection after each dose; Final dose: predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14 days after dose

  3. Maximum Observed Serum Concentration Obtained From the First Dose (Cmax14d)

    Maximum observed serum concentration (Cmax14d) of sotatercept, obtained directly from the observed concentration-time data. The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.

    Time frame: Doses 1-2: predose and postdose at 5 min (IV only) 4 hours, 3, and 7 days after each dose; Doses 3-7: predose, and postdose at 5 min after IV injection after each dose; Final dose: predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14 days after dose

  4. Maximum Observed Serum Concentration (Cmax28d) Obtained From the Combined First 2 Doses

    Maximum observed serum concentration (Cmax28d) of sotatercept, obtained directly from the observed concentration-time data combining the profiles following the first two doses. The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.

    Time frame: Doses 1-2: predose and postdose at 5 min (IV only) 4 hours, 3, and 7 days after each dose; Doses 3-7: predose, and postdose at 5 min after IV injection after each dose; Final dose: predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14 days after dose

  5. Time to Reach Maximum Observed Serum Concentration (Tmax)

    Time to maximum serum concentration (Tmax) of sotatercept, obtained directly from the observed concentration-time data. The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.

    Time frame: Doses 1-2: pre- and postdose at 5 min (IV only) 4 hrs, 3, and 7 days after each dose; Doses 3-7: pre-, and postdose at 5 min after IV injection after each dose; Final dose: pre- and postdose at 5 min (IV only), 4 hrs, 3, 7, 14, 28, 56, 84, and 112 days

  6. Estimate of Terminal Elimination Half-Life in Serum at Final Dose Only (t1/2)

    Terminal elimination half-life (T1/2). The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.

    Time frame: Predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14, 28, 56, 84, and 112 days after the final dose.

  7. Lambda (ʎz): Apparent Terminal Rate Constant (at Final Dose Only)

    Lambda, apparent terminal rate constant (final dose only). The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analysis of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.

    Time frame: Predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14, 28, 56, 84, and 112 days after the final dose

Secondary outcomes

  1. Percentage of Participants With Mean Hemoglobin ≥ 100 g/L to ≤ 120 g/L Without Rescue Medication

    The percentage of participants able to maintain a mean (Visit 14 to 17) hemoglobin concentration ≥ 100 g/L to ≤ 120 g/L without the need for rescue medication at each dose level. Mean hemoglobin value is a mean of hemoglobin concentrations from Visit 14 to Visit 17 (days 99 to 113).

    Time frame: Visit 14 to Visit 17 (days 99 to 113)

  2. Change From Baseline in Mean Hemoglobin Concentration for Visit 14 to 17 (All Participants Regardless of Rescue)

    Change in mean hemoglobin concentration between baseline and Visit 14 to 17 at each dose level. Baseline hemoglobin value is the mean of three consecutive hemoglobin concentrations with the last hemoglobin concentration done within the 7 days prior to randomization and the value obtained on the day of randomization. Visit 14 to 17 hemoglobin value is a mean of hemoglobin concentrations from Day 99 \[Visit 14\] to Day 113 \[Visit 17\].

    Time frame: Baseline and Visit 14 to Visit 17 (days 99 to 113)

  3. Change From Baseline in Mean Hemoglobin Concentration for Visit 14 to 17 (Participants Not Rescued Prior to Day 115)

    Change in mean hemoglobin concentration between baseline and Visit 14 to 17 at each dose level for participants not rescued prior to Day 115. Baseline hemoglobin value is the mean of three consecutive hemoglobin concentrations with the last hemoglobin concentration done within the 7 days prior to randomization and the value obtained on the day of randomization. Visit 14 to 17 hemoglobin value is a mean of hemoglobin concentrations from Day 99 \[Visit 14\] to Day 113 \[Visit 17\].

    Time frame: Baseline and Visit 14 to Visit 17 (days 99 to 113)

  4. Number of Participants With Adverse Events (AEs)

    Treatment-emergent adverse event (TEAE) was defined as an adverse event with start date on or after date of first dose of study drug. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participants during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. A serious adverse event is defined as any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. Severity and intensity was assessed using the following grading scale: Mild, Moderate and Severe (could be non-serious or serious).

    Time frame: From date of first dose of investigational product to 112 days after the last dose or until the last study visit, whichever period was longer. The maximum duration for any IV or SC dose was 114 days. Up to approximately 226 days.

07

Results

Posted Jun 24, 2024
Limitations and caveats
Due to a shift in the clinical development strategy for the renal sotatercept program, Part 2 of the study was not conducted; Part 2 objectives were not assessed and none of the statistical analyses in Part 2 were conducted; no safety concerns.

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection
Started7799126
Completed4436103
Not completed336323
Withdrew: Withdrawal by subject000100
Withdrew: Adverse event003010
Withdrew: Other reasons103112
Withdrew: Protocol violation100001
Withdrew: Lack of efficacy130100

Outcome measures

PrimaryArea Under the Serum Concentration-Time Curve Over Dosing Interval (AUC14d) (14 Days)

Area Under the plasma concentration-time curve over 14-day dosing interval (AUC14) for Sotatercept., The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.

Time frame:
Doses 1-2: predose and postdose at 5 min (IV only) 4 hours, 3, and 7 days after each dose; Doses 3-7: predose, and postdose at 5 min after IV injection after each dose; Final dose: predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14 days after dose
Reported as:
Mean · day*ng/mL
Area Under the Serum Concentration-Time Curve Over Dosing Interval (AUC14d) (14 Days)
day*ng/mLGroup 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection
Area Under the Serum Concentration-Time Curve Over Dosing Interval (AUC14d) (14 Days)15204.31 ± 7096.5511269.14 ± 1839.9228647.03 ± 10332.1910327.98 ± 8065.1215886.83 ± 4212.1221982.9 ± 5125.4
PrimaryArea Under the Serum Concentration- Time Curve Over From Day 1 to Day 28 (AUC28d)

Area under the plasma concentration-time curve over 28-day dosing interval (AUC28d). All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.

Time frame:
Doses 1-2: predose and postdose at 5 min (IV only) 4 hours, 3, and 7 days after each dose; Doses 3-7: predose, and postdose at 5 min after IV injection after each dose; Final dose: predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14 days after dose
Reported as:
Mean · day*ng/mL
Area Under the Serum Concentration- Time Curve Over From Day 1 to Day 28 (AUC28d)
day*ng/mLGroup 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection
Area Under the Serum Concentration- Time Curve Over From Day 1 to Day 28 (AUC28d)38361.5 ± 8589.3441500.36 ± 13647.2894106.54 ± 37204.1736065.09 ± 2281733173.4 ± 8709.1660497.8 ± 14623.13
PrimaryMaximum Observed Serum Concentration Obtained From the First Dose (Cmax14d)

Maximum observed serum concentration (Cmax14d) of sotatercept, obtained directly from the observed concentration-time data. The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.

Time frame:
Doses 1-2: predose and postdose at 5 min (IV only) 4 hours, 3, and 7 days after each dose; Doses 3-7: predose, and postdose at 5 min after IV injection after each dose; Final dose: predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14 days after dose
Reported as:
Mean · ng/mL
Maximum Observed Serum Concentration Obtained From the First Dose (Cmax14d)
ng/mLGroup 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection
Maximum Observed Serum Concentration Obtained From the First Dose (Cmax14d)2567.6 ± 1093.731024.27 ± 145.84623.61 ± 1620.66963.05 ± 659.653155.53 ± 1861.071993.58 ± 375.54
PrimaryMaximum Observed Serum Concentration (Cmax28d) Obtained From the Combined First 2 Doses

Maximum observed serum concentration (Cmax28d) of sotatercept, obtained directly from the observed concentration-time data combining the profiles following the first two doses. The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.

Time frame:
Doses 1-2: predose and postdose at 5 min (IV only) 4 hours, 3, and 7 days after each dose; Doses 3-7: predose, and postdose at 5 min after IV injection after each dose; Final dose: predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14 days after dose
Reported as:
Mean · ng/mL
Maximum Observed Serum Concentration (Cmax28d) Obtained From the Combined First 2 Doses
ng/mLGroup 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection
Maximum Observed Serum Concentration (Cmax28d) Obtained From the Combined First 2 Doses3557.93 ± 699.193868.83 ± 3614.898613.67 ± 3559.691967.55 ± 1128.693501.54 ± 2144.153161.6 ± 788.14
PrimaryTime to Reach Maximum Observed Serum Concentration (Tmax)

Time to maximum serum concentration (Tmax) of sotatercept, obtained directly from the observed concentration-time data. The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.

Time frame:
Doses 1-2: pre- and postdose at 5 min (IV only) 4 hrs, 3, and 7 days after each dose; Doses 3-7: pre-, and postdose at 5 min after IV injection after each dose; Final dose: pre- and postdose at 5 min (IV only), 4 hrs, 3, 7, 14, 28, 56, 84, and 112 days
Reported as:
Median · days
Time to Reach Maximum Observed Serum Concentration (Tmax)
daysGroup 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection
Time to Reach Maximum Observed Serum Concentration (Tmax)14.09 ± 14.0121.01 ± 16.1614.02 ± 13.9918.51 ± 15.990.1688 ± 0.003521.06 ± 20.99
PrimaryEstimate of Terminal Elimination Half-Life in Serum at Final Dose Only (t1/2)

Terminal elimination half-life (T1/2). The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analyses of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.

Time frame:
Predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14, 28, 56, 84, and 112 days after the final dose.
Reported as:
Mean · days
Estimate of Terminal Elimination Half-Life in Serum at Final Dose Only (t1/2)
daysGroup 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection
Estimate of Terminal Elimination Half-Life in Serum at Final Dose Only (t1/2)17.6 ± 4.63125.87 ± 7.12721.76 ± 3.94121.03 ± 5.422.46 ± 5.34220.39 ± 5.3
PrimaryLambda (ʎz): Apparent Terminal Rate Constant (at Final Dose Only)

Lambda, apparent terminal rate constant (final dose only). The PK population included all participants in the safety population with at least one non-missing plasma concentration data. All analysis of PK data were based on the PK population and participants were analyzed according to the treatment group to which they were randomized.

Time frame:
Predose and postdose at 5 min (IV only) 4 hours, 3, 7, 14, 28, 56, 84, and 112 days after the final dose
Reported as:
Mean · 1/day
Lambda (ʎz): Apparent Terminal Rate Constant (at Final Dose Only)
1/dayGroup 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection
Lambda (ʎz): Apparent Terminal Rate Constant (at Final Dose Only)0.0414 ± 0.00940.0282 ± 0.00710.0328 ± 0.00630.0346 ± 0.00780.0326 ± 0.00850.0355 ± 0.0077
SecondaryPercentage of Participants With Mean Hemoglobin ≥ 100 g/L to ≤ 120 g/L Without Rescue Medication

The percentage of participants able to maintain a mean (Visit 14 to 17) hemoglobin concentration ≥ 100 g/L to ≤ 120 g/L without the need for rescue medication at each dose level. Mean hemoglobin value is a mean of hemoglobin concentrations from Visit 14 to Visit 17 (days 99 to 113).

Time frame:
Visit 14 to Visit 17 (days 99 to 113)
Reported as:
Number · Percentage of participants
Percentage of Participants With Mean Hemoglobin ≥ 100 g/L to ≤ 120 g/L Without Rescue Medication
Percentage of participantsGroup 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection
Percentage of Participants With Mean Hemoglobin ≥ 100 g/L to ≤ 120 g/L Without Rescue Medication42.942.911.133.32550
SecondaryChange From Baseline in Mean Hemoglobin Concentration for Visit 14 to 17 (All Participants Regardless of Rescue)

Change in mean hemoglobin concentration between baseline and Visit 14 to 17 at each dose level. Baseline hemoglobin value is the mean of three consecutive hemoglobin concentrations with the last hemoglobin concentration done within the 7 days prior to randomization and the value obtained on the day of randomization. Visit 14 to 17 hemoglobin value is a mean of hemoglobin concentrations from Day 99 \[Visit 14\] to Day 113 \[Visit 17\].

Time frame:
Baseline and Visit 14 to Visit 17 (days 99 to 113)
Reported as:
Mean · g/L
Change From Baseline in Mean Hemoglobin Concentration for Visit 14 to 17 (All Participants Regardless of Rescue)
g/LGroup 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection
Change From Baseline in Mean Hemoglobin Concentration for Visit 14 to 17 (All Participants Regardless of Rescue)-6.9 ± 11.61-2.7 ± 6.47-2.1 ± 12.23-0.8 ± 10.03-9.9 ± 9.3-6.4 ± 12.6
SecondaryChange From Baseline in Mean Hemoglobin Concentration for Visit 14 to 17 (Participants Not Rescued Prior to Day 115)

Change in mean hemoglobin concentration between baseline and Visit 14 to 17 at each dose level for participants not rescued prior to Day 115. Baseline hemoglobin value is the mean of three consecutive hemoglobin concentrations with the last hemoglobin concentration done within the 7 days prior to randomization and the value obtained on the day of randomization. Visit 14 to 17 hemoglobin value is a mean of hemoglobin concentrations from Day 99 \[Visit 14\] to Day 113 \[Visit 17\].

Time frame:
Baseline and Visit 14 to Visit 17 (days 99 to 113)
Reported as:
Mean · g/L
Change From Baseline in Mean Hemoglobin Concentration for Visit 14 to 17 (Participants Not Rescued Prior to Day 115)
g/LGroup 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection
Change From Baseline in Mean Hemoglobin Concentration for Visit 14 to 17 (Participants Not Rescued Prior to Day 115)-7 ± 6.24-3.6 ± 7.08-0.3 ± 15.20.5 ± 10.28-13 ± 10.07-1 ± 8.05
SecondaryNumber of Participants With Adverse Events (AEs)

Treatment-emergent adverse event (TEAE) was defined as an adverse event with start date on or after date of first dose of study drug. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participants during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. A serious adverse event is defined as any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. Severity and intensity was assessed using the following grading scale: Mild, Moderate and Severe (could be non-serious or serious).

Time frame:
From date of first dose of investigational product to 112 days after the last dose or until the last study visit, whichever period was longer. The maximum duration for any IV or SC dose was 114 days. Up to approximately 226 days.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsGroup 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection
Any TEAE7396106
Any Treatment-Related TEAE111001
Any Serious TEAE303133
Any Treatment-Related Serious TEAE000000
Any TEAE leading to study drug discontinuation003010
Any Severe TEAE002012
Any TEAE Leading to Death000001

Adverse events

Collected over All-cause mortality was assessed from date of first dose to study completion (up to approximately 33 months). Serious Adverse events and other adverse events were assessed from date of first dose to 112 days after the last dose or until the last study visit, whichever period was longer, up to approximately 226 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) Injection0/7 (0%)3/7 (42.9%)7/7 (100%)
Group 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) Injection0/7 (0%)0/7 (0%)3/7 (42.9%)
Group 2: Sotatercept 0.2 mg/kg IV Injection0/9 (0%)3/9 (33.3%)9/9 (100%)
Group 2: Sotatercept 0.26 mg/kg SC Injection0/9 (0%)1/9 (11.1%)6/9 (66.7%)
Group 3: Sotatercept 0.1 - 0.4 mg/kg IV Injection0/12 (0%)3/12 (25%)9/12 (75%)
Group 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection1/6 (16.7%)3/6 (50%)6/6 (100%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventGroup 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection
Cardiac failureCardiac disorders0/70/70/90/90/121/6
Mitral valve incompetenceCardiac disorders0/70/71/90/90/121/6
Supraventricular tachycardiaCardiac disorders0/70/70/90/90/121/6
Gastrointestinal angiodysplasia haemorrhagicGastrointestinal disorders0/70/70/90/90/121/6
Device related infectionInfections and infestations0/70/70/90/90/121/6
Atrial fibrillationCardiac disorders1/70/70/91/90/120/6
Chronic gastritisGastrointestinal disorders1/70/70/90/90/120/6
ConjunctivitisInfections and infestations1/70/70/90/90/120/6
ParonychiaInfections and infestations1/70/70/90/90/120/6
Upper respiratory tract infectionInfections and infestations1/70/70/90/90/120/6
Most frequent other events
Showing 10 of 82
Most frequent other events
EventGroup 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC Injection
HeadacheNervous system disorders0/70/71/90/91/123/6
NauseaGastrointestinal disorders0/70/71/90/90/122/6
ToothacheGastrointestinal disorders0/70/70/90/90/122/6
InfluenzaInfections and infestations1/71/71/90/90/122/6
Muscle spasmsMusculoskeletal and connective tissue disorders0/71/70/93/90/122/6
HypertensionVascular disorders1/70/72/92/92/122/6
Urinary tract infectionInfections and infestations2/70/71/90/90/120/6
Arteriovenous fistula site complicationInjury, poisoning and procedural complications2/72/70/91/90/120/6
HaematuriaRenal and urinary disorders2/70/71/90/90/120/6
EpistaxisRespiratory, thoracic and mediastinal disorders1/70/72/90/90/120/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC InjectionTotal
Mean59.1 ± 15.4362.3 ± 13.0359.4 ± 15.861.9 ± 15.4361.4 ± 15.6853.7 ± 15.9360.0 ± 14.75
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC InjectionTotal
Female43435322
Male34567328
Race
Race(Participants)Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC InjectionTotal
White456811640
Black or African- American1110104
Asian2021005
American Indian/Alaska Native0100001
Ethnicity
Ethnicity(Participants)Group 1: Sotatercept 0.1 mg/kg Intravenous (IV) InjectionGroup 1: Sotatercept 0.13 mg/kg Subcutaneous (SC) InjectionGroup 2: Sotatercept 0.2 mg/kg IV InjectionGroup 2: Sotatercept 0.26 mg/kg SC InjectionGroup 3: Sotatercept 0.1 - 0.4 mg/kg IV InjectionGroup 3: Sotatercept 0.4 - 0.5 mg/kg SC InjectionTotal
Hispanic or Latino0110002
Not Hispanic or Latino768912648
08

Study locations

23 sites
  • Centre Hospitalier EpiCURA - Clinique Louis Caty de Baudour
    Baudour, 7331, Belgium
  • Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg
    Leuven, 3000, Belgium
  • CHR de la CITADELLE
    Liege, 4000, Belgium
  • KfH Nierenzentrum Coburg
    Coburg, 96450, Germany
  • Gemeinschaftspraxis und Dialysezentrum Karlstrass
    Düsseldorf, 40210, Germany
  • KfH Kuratorium für Dialyse und Nierentransplantation e.v.
    München, 80337, Germany
  • KfH Nierenzentrum Rosenheim
    Rosenheim, 83022, Germany
  • Nephrocare Faro
    Faro, 8000, Portugal
  • Hospital de Santa Maria
    Lisboa, 1649-035, Portugal
  • Nephrocare Portimao
    Portimão, 8500-311, Portugal
  • Complejo Hospitalario de Torrecardenas
    Almeria, 04009, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic of Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
  • Hospital Galdakao-Usansolo
    Galdakao, 48960, Spain
  • Servicio de Nefrologia Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, Madrid, 28222, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria, 39008, Spain
  • Hospital de Torrevieja
    Torrevieja (Alicante), 03186, Spain
  • Cambridge University Hospitals NHS Trust
    Cambridge, CB2 0QQ, United Kingdom
  • Glasgow Royal Infirmary
    Glasgow, G11 6NT, United Kingdom
  • St Georges Healthcare NHS Trust
    London, SW17 0QT, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Aug 2016, 33 months.

Results were first posted in Jun 2024, 7 years 9 months after primary completion.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 33 months is above that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2013
First posted
Dec 3, 2013
StartActual
Nov 30, 2013
Primary completionActual
Aug 31, 2016
CompletionActual
Aug 31, 2016
Results first posted
Jun 24, 2024
Last update
Jun 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01999582
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Dec 3, 2013
Start date
Nov 30, 2013
Primary completion
Aug 31, 2016
Completion
Aug 31, 2016
Results posted
Jun 24, 2024
Last update
Jun 24, 2024

Study contacts

William Smith, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion